2052 results about "Oxime" patented technology

Disclosed is an oxime ester compound represented by the following general formula (I). (In the formula, R1, R2 and R3 independently represent R11, OR11, COR11, SR11, CONR12R13 or CN; R11, R12 and R13 Independently represent a hydrogen atom, an alkyl group having 1-20 carbon atoms, an aryl group having 6-30 carbon atoms, an arylalkyl group having 7-30 carbon atoms or a heterocyclic group having 2-20 carbon atoms; R4 and R5 independently represent R11, OR11, SR11, COR11, CONR12R13, NR12COR11, OCOR11, COOR11, SCOR11, OCSR11, COSR11, CSOR11, CN, a halogen atom or a hydroxy group; and a and b independently represent a number of 0-3.)

A pharmaceutical composition comprising a co-crystal of an API and a co-crystal former; wherein the API has at least one functional group selected from ether, thioether, alcohol, thiol, aldehyde, ketone, thioketone, nitrate ester, phosphate ester, thiophosphate ester, ester, thioester, sulfate ester, carboxylic acid, phosphonic acid, phosphinic acid, sulfonic acid, amide, primary amine, secondary amine, ammonia, tertiary amine, sp2 amine, thiocyanate, cyanamide, oxime, nitrile diazo, organohalide, nitro, s-heterocyclic ring, thiophene, n-heterocyclic ring, pyrrole, o-heterocyclic ring, furan, epoxide, peroxide, hydroxamic acid, imidazole, pyridine and the co-crystal former has at least one functional group selected from amine, amide, pyridine, imidazole, indole, pyrrolidine, carbonyl, carboxyl, hydroxyl, phenol, sulfone, sulfonyl, mercapto and methyl thio, such that the API and co-crystal former are capable of co-crystallizing from a solution phase under crystallization conditions.

Disclosed are compounds that include two or more haptens conjugated by a spacer or a carrier. The haptens may include diethylenetriaminepentaacetate (DTPA), histimine-succinyl-glutamine (HSG), or combinations of DTPA and HSG. The compound also includes an effector molecule which may be conjugated to one or more of the haptens, the spacer / carrier, or both. The effector molecule may be conjugated by a number of linkages including an ester linkage, an imino linkage, an amino linkage, a sulfide linkage, a thiosemicarbazone linkage, a semicarbazone linkage, an oxime linkage, an ether linkage, or combinations of these linkages. Also disclosed are methods of synthesizing the compounds and / or precursors of the compounds.

The invention relates to the photoinitiator technical field, in particular to an oxime ester photoinitiator and a preparation method thereof. A carbazole oxime ester photoinitiator has a structural general formula as the right formula, R=formula (1), n=0-5, m=3 or 4, R radical is aliphatic ketone with cyclane, the cyclane is cycloaliphatic ring from cyclopropane to cyclooctane, branched-chain aliphatic hydrocarbon connects the cyclane and the ketone, and the chain usually has 0-6 carbon atoms. The carbazole oxime ester photoinitiator with the structure is a brand-new compound with good photoinitiator performance, and solves the problem of poor sensitivity, thermal stability and solubility of the existing carbazole oxime ester photoinitiators.

A pharmaceutical composition comprising a co-crystal of an API and a co-crystal former; wherein the API has at least one functional group selected from ether, thioether, alcohol, thiol, aldehyde, ketone, thioketone, nitrate ester, phosphate ester, thiophosphate ester, ester, thioester, sulfate ester, carboxylic acid, phosphonic acid, phosphinic acid, sulfonic acid, amide, primary amine, secondary amine, ammonia, tertiary amine, sp2 amine, thiocyanate, cyanamide, oxime, nitrile diazo, organohalide, nitro, s-heterocyclic ring, thiophene, n-heterocyclic ring, pyrrole, o-heterocyclic ring, furan, epoxide, peroxide, hydroxamic acid, imidazole, pyridine and the co-crystal former has at least one functional group selected from amine, amide, pyridine, imidazole, indole, pyrrolidine, carbonyl, carboxyl, hydroxyl, phenol, sulfone, sulfonyl, mercapto and methyl thio, such that the API and co-crystal former are capable of co-crystallizing from a solution phase under crystallization conditions.

The invention relates to a process for preparing a conjugate comprising combining an amino-oxy homofunctional or heterofunctional reagent with an entity chosen from polysaccharides, oligosaccharides, carbohydrates, and carbohydrate-containing molecules containing at least one carbonyl group, to form a polysaccharide, oligosaccharide, carbohydrate, or carbohydrate-containing molecule functionalized via at least one oxime linkage. The functionalized compound is then reacted either directly or indirectly with a protein moiety to form a protein-carbohydrate conjugate that may be used as a vaccine.

The present invention provides a tetrazoyloxime derivative which is less likely to cause chemical injury to useful plants and is also superior in chemical efficacy to a conventional hetero ring-substituted oxime derivative. A tetrazoyloxime derivative represented by the general formula (1): <CHEM> X represents a hydrogen atom, a halogen atom, an alkyl group, an alkoxy group, a cyano group, a methanesulfonyl group, a nitro group, a trifluoromethyl group, or an aryl group; A represents a 1-alkyltetrazoyl-5-yl group or a 5-alkyltetrazoyl-1-yl group; and Het represents a pyridyl group having a substituent or a thiazoyl group having a substituent, and a plant disease controlling agent containing the same as an active ingredient are disclosed.

A pharmaceutical composition comprising a co-crystal of an API and a co-crystal former; wherein the API has at least one functional group selected from ether, thioether, alcohol, thiol, aldehyde, ketone, thioketone, nitrate ester, phosphate ester, thiophosphate ester, ester, thioester, sulfate ester, carboxylic acid, phosphinic acid, phosphonic acid, sulfonic acid, amide, primary amine, secondary amine, ammonia, tertiary amine, imine, thiocyanate, cyanamide, oxime, nitrile diazo, organohalide, nitro, S-heterocyclic ring, thiophene, N-heterocyclic ring, pyrrole, 0-heterocyclic ring, furan, epoxide, peroxide, hydroxamic acid, imidazole, pyridine and the co-crystal former has at least one functional group selected from amine, amide, pyridine, imidazole, indole, pyrrolidine, carbonyl, carboxyl, hydroxyl, phenol, sulfone, sulfonyl, mercapto and methyl thio, such that the API and co-crystal former are capable of co-crystallizing from a solution phase under crystallization conditions.

Sulfonate salts have the formula: R1COOCH2CH2CF2CF2SO3−M+ wherein R1 is alkyl, aryl or hetero-aryl, M+ is a Li, Na, K, ammonium or tetramethylammonium ion. Onium salts, oxime sulfonates and sulfonyloxyimides derived from these salts are effective photoacid generators in chemically amplified resist compositions.

An ink set for inkjet recording is provided that includes at least a colored liquid composition comprising at least a radically polymerizable compound, a photopolymerization initiator, and a colorant, and an undercoat liquid composition comprising at least a radically polymerizable compound and a photopolymerization initiator, the colored liquid composition comprising as the photopolymerization initiator at least one type of α-aminoacetophenone compound, and the undercoat liquid composition comprising as the photopolymerization initiator at least one type of compound selected from the group consisting of an acylphosphine oxide compound, an α-hydroxyacetophenone compound, and an oxime ester compound. There is also provided an inkjet recording method employing the ink set for inkjet recording, the method including a step of applying the undercoat liquid composition on top of a recording medium, a step of semi-curing the undercoat liquid composition, and a step of carrying out image formation by discharging the colored liquid composition on top of the semi-cured undercoat liquid composition.

Compounds of formula I, wherein R1-R9 and n are defined herein, and pharmaceutical compositions and kits containing these compounds are provided. Also provided are methods of inducing contraception, providing hormone replacement therapy, treating cycle-related symptoms, or treating or preventing benign or malignant neoplastic disease using the compounds of formula I or formula II, wherein R3-R5, R10, and R11 are defined herein.

There is closed a flux which is designed to be used in a soldering using a lead-free and zinc-free solder containing tin as a major component and not containing lead, the soldering being adapted to be applied to a surface portion which is constituted by a copper-based metal and / or a nickel-based metal (excluding the case where the surface portion is constituted by electroless nickel plating), wherein the flux contains at least one kind of material selected from the group consisting of a copper-based metal, a nickel-based metal, an inorganic salt of copper-based metal and / or a nickel-based metal, an inorganic complex of copper-based metal and / or a nickel-based metal, and an organic complex of copper-based metal and / or a nickel-based metal (a metal complex of an organic compound where atoms of N, O and S in amine (excluding nitrogen-containing hetrocyclic compounds), imine (excluding nitrogen-containing hetrocyclic compounds), oxime, ketone, alkoxy and thioketone are coordinated with a metal). There is also closed a method of manufacturing a lead-free soldered body wherein this flux is employed.

A polymerizable polymeric photoinitiator according to Formula (I):wherein:PL represents an n+m+p-functional polymeric core;n and m independently represent an integer from 1 to 30;p represents an integer from 0 to 10;o is 0 or 1;INI represents a group selected from the group consisting of a benzophenone, a thioxanthone, a carbazole, a anthraquinone, a camphor quinone, an α-hydroxyalkylphenone, an α-aminoalkylphenone, an acylphosphine oxide, a bisacyl phosphine oxide, an acylphosphine sulfide, a phenyl glyoxalate, a benzoin ether, a benzyl ketal, an α-dialkoxyacetophenone, a carbazolyl-O-acyl-oxime, an α-haloarylketone and an α-haloaryl sulfone;L3 and L4 represent a substituted or unsubstituted divalent linking group comprising 1 to 14 carbon atoms;A represents a radically polymerizable functional group selected from the group consisting of an acrylate, a methacrylate, a styrene, an acryl amide, a methacryl amide, a maleate, a fumarate, an itaconate, an vinyl ether, an allyl ether, an allyl ester, a maleimide, a vinyl nitrile and a vinyl ester; andR4 represents a substituted or unsubstituted alkyl group.Radiation curable compositions containing the polymerizable polymeric photoinitiator and methods for preparing the polymerizable polymeric photoinitiator are also disclosed.

The invention relates to an application of a carbazole oxime ester compound serving as a photoinitiator in a photopolymerisable acrylate composition, the photopolymerisable acrylate composition containing the carbazole oxime ester compound and an application thereof. The composition presents excellent suitability by the combination of the specific photoinitiator and specific photopolymerisable acrylate monomer, and has high storage stability, higher light sensitivity in a short wave position, and excellent dissolvability performance; and when the composition is polymerized, the composition has the advantages of fast solidification speed, little pollution, energy conservation, high exposal efficiency and small exposal dosage, meanwhile, the solidified image pattern is fine and complete without defect and scum, and the membrane has good hardness.

The invention relates to a pyrazole oxime ester photoinitiator with a chemical formula (I). The photoinitiator has excellent application performance and extremely high photographic performance, can greatly improve the photocuring performance when being applied to photosensitive compositions and remarkably improve the production efficiency of the photosensitive compositions in the application fields, such as the preparation of color filters, and the like. The invention also relates to a preparation method of the pyrazole oxime ester photoinitiator and the application of the pyrazole oxime ester photoinitiator to the photosensitive compositions.

The invention belongs to the field of organosilicon, and particularly relates to an organosilicon coating and a preparation method thereof. The organosilicon coating is characterized in that the organosilicon coating comprises 90 to 120 parts of Alpha, Omega-dihydroxy polydimethylpolysiloxane, 10 to 30 parts of MQ resin, 10 to 30 parts of white carbon black, 0.3 to 1 part of vulcanization accelerators, 2 to 3 parts of methyl-tri-(butanone-oxime) silane, 2 to 3 parts of vinyl tributanoximo silane, 1 to 3 parts of propylamino triethoxy silane, 1 to 2 parts of 3-glycidyl ether oxypropyl trimethoxysilane and 70 to 90 parts of solvent. The preparation method comprises the steps of raw material selection, raw material weighing, rubber compound drying, rubber compound preparation, and the like. The organosilicon elastic coating disclosed by the invention has low viscosity and high fluidity, can be rapidly self-leveled and filled after being coated, has a high curing speed at room temperature, needs short surface drying time and curing time, has excellent electric insulation performance, high strength, low hardness, high elasticity and good toughness after being cured, has self-repairing performance and an elongation percentage reaching 200 to 500 percent, has good bonding performance, has shear strength of 2 to 5MPa over aluminum, has little odor, cannot corrode a matrix, adopts solvent oil as the solvent, can effectively insulate and protect the surfaces of printed circuit boards (PCB) and electronic devices, and can also used as other elastic coatings needing insulation performance and anticorrosion performance.

The present invention provides a negative dye-containing curable composition comprising at least (A) an alkali-soluble binder, (B) an organic solvent-soluble dye, (C) a photopolymerization initiator, (D) a radical-polymerizable monomer and (E) an organic solvent, wherein the organic solvent-soluble dye (B) comprises at least one kind of azomethine-type dye represented by the following formula (I) and at least one kind of tetraazaporphyrin-type dye represented by the following formula (A), and the photopolymerization initiator (C) is an oxime-type compound, wherein R1 represents a hydrogen atom or a substituent group; R2 to R5 each represent a hydrogen atom or a substituent group, R6 to R7 each represent an alkyl group, alkenyl group, aryl group or heterocyclic group, Za and Zb each represent —N═ or —C(R8)═; R8 represents a hydrogen atom, alkyl group, aryl group or heterocyclic group; M1 represents a metal, and Z1 to Z4 each represent an atomic group forming a 6-membered ring composed of atoms selected from carbon and nitrogen.

A composition and method are provided for alleviating the dermatological signs of intrinsic and extrinsic aging. A topical formulation containing a cosmeceutically active base, wherein the formulation provides a pH in the range of about 8.0 to 13.0 at the skin surface, is applied to the skin in order to prevent or treat aging-related skin conditions such as wrinkles, dry skin, age spots, sun damage (particularly UV radiation-induced oxidative stress), blemishes, hyperpigmented skin, age spots, increased skin thickness, loss of skin elasticity and collagen content, dry skin, lentigines and melasmas. The cosmeceutically active base is either an inorganic base, such as an inorganic hydroxide, an inorganic oxide, or a metal salt of a weak acid, or an organic base, particularly a nitrogenous base such as may be selected from primary amines, secondary amines, tertiary amines, amides, oximes, nitrites, aromatic and non-aromatic nitrogen-containing heterocycles, urea, and mixtures thereof.

The invention relates to a single-component ketone-oxime-removing type silicon rubber sealant. The single-component ketone-oxime-removing type silicon rubber sealant comprises the following components in part by weight: (A) 100 parts of alpha, omega-dihydroxyl polydimethylsiloxane, (B) 10 to 30 parts of dimethyl silicon oil, (C) 7 to 12 parts of ketone-oxime-removing type crosslinking agent, (D) 1 to 5 parts of silane coupling agent with a special structure, (E) 50 to 150 parts of reinforcing filler and (F) 0.1 to 1 part of catalyst. The sealant comprises the silane coupling agent with the special structure. Due to introduction of the coupling agent, the sealant has excellent bonding durability, and particularly high bonding strength retention ratio under high-temperature high-humidity conditions and a water boiling environment. In addition, due to introduction of the coupling agent, the curing speed of the silicon rubber sealant is increased, and the coupling agent can be widely applied to bonding and sealing of industries such as electrons, automobiles, home appliances and the like.

The present invention relates to the use of inhibitors of the action of eukaryotic-type Acetyl-CoA carboxylase for controlling insect pests. The inhibitors are selected from arylphenoxypropionates and cyclohexanedione oximes, or their mixtures which may be used together with suitable additives, excipients and carriers. The invention further relates to an insecticidal composition comprising inhibitors of eukaryotic-type Acetyl-CoA carboxylase and further to a method for controlling undesired insect pests by applying an effective amount of eukaryotic-type Acetyl-CoA carboxylase inhibitors.

The present invention relates to biodegradable biocompatible polyketals, methods for their preparation, and methods for creating animals by administration of biodegradable biocompatible polyketals. In one aspect, a method for forming the biodegradable biocompatible polyketals comprises combining a glycol-specific oxidizing agent with a polysaccharide to form an aldehyde intermediate, which is combined with a reducing agent to form the biodegradable biocompatible polyketal. The resultant biodegradable biocompatible polyketals can be chemically modified to incorporate additional hydrophilic moieties. A method for treating animals includes the administration of the biodegradable biocompatible polyketal in which biologically active compounds or diagnostic labels can be disposed. The present invention also relates to chiral polyketals, methods for their preparation, and methods for use in chromatographic applications, specifically in chiral separations. A method for forming the chiral polyketals comprises combining a glycol-specific oxidizing agent with a polysaccharide to form an aldehyde intermediate, which is combined with a suitable reagent to form the chiral polyketal. A method for use in chiral separations includes the incorporation of the chiral polyketals in the mobile phase during a chromatographic separation, or into chiral stationary phases such as gels. The present invention further relates to chiral polyketals as a source for chiral compounds, and methods for generating such chiral compounds.

The invention discloses a method for preparing azithromycin. The method comprises the following steps of: in acid aqueous solution and under an action of potassium borohydride, performing the reduction reaction of erythromycinA6, 9-imine ether represented by a formula II, then performing methylation reaction, and putting the reaction products in a mixed solvent of water and halogenated hydrocarbons for hydrolysis reaction so as to obtain the azithromycin represented by a formula I. In the method, the reducer is properly consumed, the yield is high, and the cost of the preparation of the azithromycin is obviously reduced. The invention also relates to a method for preparing the erythromycinA6, 9-imine ether and erythromycinA9-oxime.

Sulfonate salts have the formula: HOCH2CH2CF2CF2SO3−M+ wherein M+ is a Li, Na, K, ammonium or tetramethylammonium ion. Onium salts, oxime sulfonates and sulfonyloxyimides derived from these salts are effective photoacid generators in chemically amplified resist compositions.

Hydrazino, oxyamino and carbonyl-based monomers and methods for incorporation into oligonucleotides during enzymatic synthesis are provided. Modified oligonucleotides are provided that incorporate the monomers provided herein. Immobilized oligonucleotides and oligonucleotide conjugates that contain covalent hydrazone or oxime linkages are provided. Methods for preparation of surface bound oligonucleotides are provided. Methods for the preparation of oligonucleotide conjugates are also provided.

A single component ketonic oxime type room temperature silastic combination contains organic siloxane polymer of 100 parts by weight, inorganic filling of 0.1 to 20 parts by weight and crosslinking agent of 3 to 45 parts by weight, wherein, the crosslinking agent contains aniline methyl trepibutone oximido silane and at least one kind of methyl trepibutone oximido silane, phenyl trepibutone oximido silane and tetrahedralpibutone oximido silane. The single component ketonic oxime type room temperature silastic composite disclosed in the invention has good leveling property and surface dry time so as to ensure that the interior of the silastic composite can dry completely, ensure the water content consistent internally and externally and overcome the case of facial crack. Being applicable for novel auxiliary material in the processes of positioning, cementing, sealing and coating package for the components of electronic products and electric equipments, the invention has good insulating, dustproof, dampproof, anticorrosive and earthquake-proof effects.